Unlocking the full potential of CRISPR genome editing requires continuous innovation.
We are committed to optimizing current tools, and developing new ones. Many antibiotics, enzymes, drugs, and research tools like CRISPR-Cas9 are the repurposed natural products of microbes. To discover novel molecules, the IGI gathers genetic information from thousands of previously unknown bacteria and archaea. We also need more options for safely and reliably delivering editing tools to agricultural crops and the parts of the human body that are harmed by mutations. The IGI is developing cross-cutting new approaches for the delivery of genome editing tools. We are building upon foundational CRISPR-Cas technologies to create more precise and powerful tools for manipulating the genome.
The delivery challenge for genome editing therapies is the single greatest impediment to widespread use of CRISPR-based therapies for genetic diseases and beyond. The IGI Delivery Collective is a collaborative effort working to develop new technology that enables or improves access to therapeutic genome editing.